<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2221" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="1118" end="1120"/>
    <type:ORR xmi:id="17" sofa="6" begin="1125" end="1128"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="1236" end="1247"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="1279" end="1290"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1527" end="1538"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1571" end="1582"/>
    <type:OSMean xmi:id="37" sofa="6" begin="1651" end="1659"/>
    <type:OSMean xmi:id="41" sofa="6" begin="1691" end="1701"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: Sorafenib, an oral multikinase inhibitor, has shown preliminary activity&#13;&#10;in non-small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated &#13;&#10;with erlotinib with or without sorafenib in this multicenter phase II trial.&#13;&#10;PATIENTS AND METHODS: Key eligibility criteria included the following: stage IIIB&#13;&#10;or IV NSCLC; one to two prior regimens; Eastern Cooperative Oncology Group&#13;&#10;performance status of 0 to 2; and measurable disease. Patients were randomly&#13;&#10;assigned 2:1 to sorafenib (400 mg orally twice a day) plus erlotinib (150 mg&#13;&#10;orally daily) or placebo plus erlotinib and stratified by squamous/nonsquamous&#13;&#10;histology and prior bevacizumab. Treatment efficacy, measured by progression-free&#13;&#10;survival (PFS) and overall response rate (ORR), was compared. Treatment of 168&#13;&#10;patients allowed detection of 40% improvement in the historical PFS of 2.2 months&#13;&#10;with single-agent erlotinib.&#13;&#10;RESULTS: One hundred sixty-eight patients enrolled from February 2008 to February&#13;&#10;2009. Clinical characteristics of the two groups were similar. ORRs for&#13;&#10;sorafenib/erlotinib and placebo/erlotinib were 8% and 11%, respectively (P =&#13;&#10;.56); disease control rates were 54% and 38%, respectively (P = .056). Median PFS&#13;&#10;was 3.38 months for sorafenib/erlotinib versus 1.94 months for placebo/erlotinib &#13;&#10;(hazard ratio, 0.86; 95% CI, 0.60 to 1.22; P = .196). Seventy-two patients&#13;&#10;consented to analyses of tumor epidermal growth factor receptor (EGFR). In 67&#13;&#10;patients with EGFR wild-type (WT) tumors, median PFS was 3.38 months for&#13;&#10;sorafenib/erlotinib versus 1.77 months for placebo/erlotinib (P = .018); median&#13;&#10;overall survival (OS) was 8 months for sorafenib/erlotinib versus 4.5 months for &#13;&#10;placebo/erlotinib (P = .019). An OS advantage for sorafenib/erlotinib was&#13;&#10;suggested among 43 patients with fluorescent in situ hybridization (FISH)&#13;&#10;EGFR-negative tumors (P = .064). Both regimens were tolerable, with modest&#13;&#10;toxicity increase with sorafenib.&#13;&#10;CONCLUSION: Although there was little difference in ORR or PFS, subset analyses&#13;&#10;in EGFR WT and EGFR FISH-negative patients suggest a benefit for the combination &#13;&#10;of erlotinib/sorafenib compared with single-agent erlotinib with respect to PFS&#13;&#10;and OS."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33 37 41"/>
</xmi:XMI>
